Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.
Glen Barber was named director of the Center for Innate Immunity and Inflammation within the Pelotonia Institute for Immuno-Oncology at the Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute.
Tiffany Seagroves joined the Tulane Cancer Center and Tulane University School of Medicine as a professor in the John W. Deming Department of Medicine, Section of Hematology and Medical Oncology.
Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant from NCI to advance their work in personalizing cancer treatment.
Sanaz Memarzadeh of UCLA has received two grants totaling $4.1 million to develop advanced cell-based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.
The University of Arkansas for Medical Sciences has been awarded a $1.3 million grant from NIH for its Arkansas Technology and Data Science in Health and Medicine program.
Stephan Braun was named chief medical officer of ImCheck Therapeutics.
A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.
Genentech, a member of the Roche Group, announced that the phase II/III SKYSCRAPER-06 study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 [95% CI: 1.02,1.57] and overall survival at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature.
